Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00046072 · ClinicalTrials.gov registry record · Phase 2

A Safety and Efficacy Study of Intravenous E5564 in Patients With Severe Sepsis

A Phase 2 study, sponsored by Eisai.

Completed
Registry status
Phase 2
Development phase
300
Enrollment target

NCT00046072: Completed Phase 2 study, sponsored by Eisai.

NCT00046072 is a Phase 2 study that has completed, run by Eisai. The registered enrollment target is 300 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (126% higher). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00046072, a Phase 2 study, has completed, sponsored by Eisai.

COMPLETED
Registry status
Phase 2
Development phase
300 participants
Enrollment target

Study Summary

Sepsis is a serious condition where there is inflammation and damage to body tissue, usually caused by an infection. This infection can lead to decreased function of vital body organs and in some cases may lead to permanent health problems or death. Much of the injury is due to endotoxin, a harmful substance produced by certain types of bacteria. An endotoxin antagonist is designed to block the effects of endotoxin. This study is designed to study the safety and efficacy when treating patients with severe sepsis.

Interventions

  • DRUG E5564

Trial Details

FieldValue
Enrollment Target 300 participants
Start Date 2001-10
Est. Completion 2005-04
Phase Phase 2
Eisai

287 total trials

What the finished NCT00046072 record still lists

NCT00046072 is an interventional study that assigns participants to a tested intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (126% higher).

The record links to 0 conditions, and to 1 intervention - of which E5564 is the first listed.

NCT00046072 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00046072 about?

NCT00046072 is a clinical study titled "A Safety and Efficacy Study of Intravenous E5564 in Patients With Severe Sepsis". Sepsis is a serious condition where there is inflammation and damage to body tissue, usually caused by an infection. This infection can lead to decreased function of vital body organs and in some cases may lead to permanent health problems or death. Much of the injury is due to endotoxin, a harmful...

What is the current status of trial NCT00046072?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 300 participants. The study started on 2001-10. Estimated completion is 2005-04.

What interventions are being tested in trial NCT00046072?

The interventions under investigation include: E5564 (DRUG).

Who is sponsoring clinical trial NCT00046072?

This trial is sponsored by Eisai, which has 287 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00046072's enrollment target sits among peer trials

300 167th of 2000 higher than 1,813 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00353483 · 300 participants

    Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells

  • NCT00588185 · 300 participants · NA

    [18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer

  • NCT00682032 · 300 participants · NA

    The Effect of Beta-glucan in Non-Small Cell Lung Cancer

  • NCT00870064 · 300 participants · NA

    The Treatment of Type I Open Fractures in Pediatrics

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00046072, the US trial registry maintained by the National Library of Medicine. NCT00046072 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.